Interim results of a Phase 2/3 trial showed Moderna's Covid-19 vaccine was well-tolerated and generated a robust immune response in children ages 6 to 11, the company said Monday.
Business daily
Merkez mahallesi mutlu han sokak no:17/2 Bartın/Sakarya
info@businessdaily.com.tr